Lindsay M. Burt
( out of 55 reviews )

Lindsay M. Burt, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
Salt Lake City
801-581-2396

Sugar House Health Center

Salt Lake City
801-581-2000

  • Lindsay Burt, MD, a Huntsman Cancer Institute (HCI) physician, is a clinical track associate professor in the Department of Radiation Oncology at the University of Utah. She is a member of the multidisciplinary Central Nervous System, Gynecology, Pediatric, and Breast teams.

    Dr. Burt’s clinical expertise is in delivering intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS), image guided radiation therapy (IGRT), volumetric modulated arc therapy (VMAT), accelerated partial breast irradiation (APBI), and high dose rate (HDR) and low dose rate (LDR) brachytherapy.

    Dr. Burt earned a bachelor’s degree in Biology-Chemistry at Claremont McKenna College in Claremont, CA. She went on to complete medical school at the University of Utah School of Medicine and residency at the University of Utah Department of Radiation Oncology in Salt Lake City, UT. She is passionate about leadership, promoting education, and research. She served as the Chair of the Association of Residents in Radiation Oncology (ARRO) Executive Committee while she was a resident and was a member of many committees at the University of Utah. She is currently a member of many American Society for Radiation Oncology (ASTRO) subcommittees and involved in many research projects. She is involved in clinical trials and has completed translational, clinical and database research.

    Specialties

    Board Certification

    American Board of Radiology (Radiation Oncology)

    Patient Rating

    4.9 /5
    ( out of 55 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 22, 2024
    HUNTSMAN CANCER CENTER

    Dr Burt and her team took care of me with respect and kindness. She listened to concerns, questions and addressed them so we understood treatment options and then surveillance. She was professional and compassionate and helped me to trust and feel very comfortable in her care. Particularly appreciated her cues and sharing what she sees and feels during each examination . Very grateful for the excellent care Dr Burt and her team provided.

    July 18, 2024
    HUNTSMAN CANCER CENTER

    Doctor Lindsay Burt is amazing! She explains your medical issues in clear terms and a caring manner, and is very personable and easy to talk with. I just can't say enough good things about her!!

    July 13, 2024
    HUNTSMAN CANCER CENTER

    She was a BREATH OF FRESH AIR!!!!! She opened the door to the room where I was waiting, and in walked a world of hope, the freshest air to inhale, and the warmest sunshine that wrapped a blanket of hugs around my body recovering from a disease in a world broken by corruption and sin.

    July 07, 2024
    SUGAR HOUSE HEALTH CENTER

    She was very kind and asked about how I'm doing and listened very well as I gave a report on my health. She was very empathetic and was clear on expectations and things I could do to manage side effects

    June 09, 2024
    HUNTSMAN CANCER CENTER

    She explained my condition and the possible procedure for treatment. She showed MY CAT Scans rather than a demonstration. She showed journal diagrams of the instruments and use of them.

    May 16, 2024
    HUNTSMAN CANCER CENTER

    Dr Burt was absolutely wonderful! Can't say enough good about her. Very professional, very caring, extremely good listener. Shared info in a positive vibrant happy way!

    May 15, 2024
    HUNTSMAN CANCER CENTER

    Doctor Burt is a kind and caring doctor. Listened to me and we had a great interaction.

    April 29, 2024
    FARMINGTON HEALTH CENTER

    It is hard to remember everyone but they all seem anxious to help and get me better.

    April 26, 2024
    HUNTSMAN CANCER CENTER

    Lindsay immediately recognized that she was an incorrect referral and we worked together to understand why. She was a great listener and had good advice for my future treatment.

    See More Patient Comments

  • Lindsay Burt, MD, a Huntsman Cancer Institute (HCI) physician, is a clinical track associate professor in the Department of Radiation Oncology at the University of Utah. She is a member of the multidisciplinary Central Nervous System, Gynecology, Pediatric, and Breast teams.

    Dr. Burt’s clinical expertise is in delivering intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS), image guided radiation therapy (IGRT), volumetric modulated arc therapy (VMAT), accelerated partial breast irradiation (APBI), and high dose rate (HDR) and low dose rate (LDR) brachytherapy.

    Dr. Burt earned a bachelor’s degree in Biology-Chemistry at Claremont McKenna College in Claremont, CA. She went on to complete medical school at the University of Utah School of Medicine and residency at the University of Utah Department of Radiation Oncology in Salt Lake City, UT. She is passionate about leadership, promoting education, and research. She served as the Chair of the Association of Residents in Radiation Oncology (ARRO) Executive Committee while she was a resident and was a member of many committees at the University of Utah. She is currently a member of many American Society for Radiation Oncology (ASTRO) subcommittees and involved in many research projects. She is involved in clinical trials and has completed translational, clinical and database research.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Primary
    Board Certification
    American Board of Radiology (Radiation Oncology)

    Education history

    Certification Quality Improvement - University of Utah Certification
    Certification Health Science Leadership Program - University of Utah David Ecceles School of Business Certification
    Chief Resident Radiation Oncology - University of Utah, Huntsman Cancer Hospital Chief Resident
    Residency Radiation Oncology - University of Utah, Huntsman Cancer Hospital Resident
    Internship Transitional Year - Sacred Heart Medical Center Transitional Internship
    Professional Medical Medicine - University of Utah School of Medicine M.D.
    Undergraduate Boise State University, Honors College
    Undergraduate Biology-Chemistry - Claremont McKenna College B.A.
    Undergraduate Chemical Engineering with Biomedical specialization - Willamette University

    Selected Publications

    Journal Article

    1. Cole KL, Earl ER, Findlay MC, Sherrod BA, Tenhoeve SA, Kunzman J, Cannon DM, Akerley W, Burt L, Seifert SB, Goldman M, Jensen RJ (2024). Assessing Survival in Non-Small Cell Lung Cancer Brain Metastases After Stereotactic Radiosurgery: Before and After the Start of the Targetable Mutation Era. J Neurooncol.
    2. Gravbrot N, Rock CB, Weil CR, Rock CB, Burt LM, DeCesaris CM, Jensen RL, Shrieve DC, Cannon DM (2024). Gross tumor and intracranial control benefits with fractionated radiotherapy compared to stereotactic radiosurgery for patients with WHO grade 2 meningioma. World Neurosurg. (Read full article)
    3. Gravbrot N, Weil CR, DeCesaris CM, Gaffney DK, Suneja G, Burt LM (2024). Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer. Eur J Cancer, 201, 113913. (Read full article)
    4. Rock CB, Weil CR, Rock CB, Gravbrot N, Burt LM, DeCesaris C, Menacho ST, Jensen RL, Shrieve DC, Cannon DM (2024). Patterns of failure after radiosurgery for WHO grade 1 or imaging defined meningiomas: Long-term outcomes and implications for management. J Clin Neurosci, 120, 175-180. (Read full article)
    5. Huang YJ, DeCesaris CM, Sarkar V, Zhao H, Kunz J, Nelson G, Li X, Suneja G, Burt LM, Gaffney DK (2023). Image-guided preplanning workflow for high-dose-rate interstitial brachytherapy for gynecological malignancies. Brachytherapy, 23(1), 25-34. (Read full article)
    6. Kunz JN, Huang YJ, Casper AC, Suneja G, Burt LM, Jhingran A, Joyner MM, Harkenrider MM, Small W Jr, Grant JD, Kidd EA, Boucher K, Gaffney DK (2023). Dosimetric Evaluation of Organs at Risk From SAVE Protocol. Int J Radiat Oncol Biol Phys. (Read full article)
    7. Jessica Kunzman, Ryan Hutten, Kristen Kelley, Kate Harris, David K Gaffney, Cristina Decesaris, Gita Suneja, Lindsay M Burt (2023). Treatment patterns for leiomyosarcomas, endometrial stromal sarcomas and adenosarcomas: a national cancer database study. European Journal of Gynaecological Oncology, 44(2), 25 - 31.
    8. Lindsay M Burt, Yuji Chen, Alison Fraser, John Snyder, Vikrant Deshmukh, Michael Newman, Paul Thielking, David Gaffney, Mia Hashibe (2023). Development of mental health disorders in endometrial cancer survivors and the impact on overall survival—a population-based cohort study. European Journal of Gynaecological Oncology, 44(1), 51-61.
    9. Christopher R Weil, Fadi Haroun, Kevin Guo, Ryan D Kraus, Zhao Hui, Lindsay M Burt, Gita Suneja, Cristina M Decesaris, Y Jessica Huang, David K Gaffney (2023). Importance of radiographic tumor regression during radiotherapy in squamous cell versus adenocarcinoma of the uterine cervix as assessed by MRI and cone beam CT. European Journal of Gynaecological Oncology, 44(1), 68-78.
    10. Kundu B, Brock AA, Garry JG, Jensen RL, Burt LM, Cannon DM, Shrieve DC, Rolston JD (2022). Outcomes using linear accelerator stereotactic radiosurgery for the treatment of trigeminal neuralgia: A single-center, retrospective study. Surg Neurol Int, 13, 246. (Read full article)
    11. Kraus RD, Weil CR, Frances Su FC, Cannon DM, Burt LM, Mendez JS (2022). Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients. Neurooncol Pract, 9(5), 380-389. (Read full article)
    12. Peterson JS, Peckham ME, Poppe MM, Burt LM, Shrieve DC, Cannon DM (2022). Delineating the Subarachnoid Space in the Adult Lumbosacral Spine Using Computed Tomographic Myelography: An Aid for Clinical Target Volume Delineation in Craniospinal Irradiation. Adv Radiat Oncol, 7(5), 100994. (Read full article)
    13. Weil CR, Lew FH, Williams VM, Burt LM, Ermoian RP, Poppe MM (2022). Patterns of Care and Utilization Disparities in Proton Radiation Therapy for Pediatric Central Nervous System Malignancies. Adv Radiat Oncol, 7(6), 100868. (Read full article)
    14. Hutten RJ, Fenlon JB, Kessel AC, Straessler KM, Huang YJ, Gaffney DK, Suneja G, Zempolich K, Burt LM (2022). Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma. Brachytherapy. (Read full article)
    15. Hsieh K, Housri N, Haffty B, Smith B, Burt LM (2021). Radiation Oncologists' Views on Breast Radiation Therapy Guidelines: Utilizing an Online Q&A Platform to Assess Current Views on Whole-Breast Irradiation Therapy. Clin Breast Cancer, 21(5), 408-416. (Read full article)
    16. Burt LM, McCormak M, Lecuru F, Kanyike DM, Bvochora-Nsingo M, Ndlovu N, Scott AA, Anorlu RI, Sharma V, Plante M, Nyongesa C, Tigeneh W, Fakie N, Suneja G, Gaffney DK (2021). Cervix Cancer in Sub-Saharan Africa: An Assessment of Cervical Cancer Management. JCO Glob Oncol, 7, 173-182. (Read full article)
    17. Wei M, Wang X, Zimmerman DN, Burt LM, Haaland B, Henry NL (2021). Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer. Breast Cancer Res Treat, 187(1), 287-294. (Read full article)
    18. Parsons MW, Whipple NS, Poppe MM, Mendez JS, Cannon DM, Burt LM (2020). The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma. J Neurooncol, 151(2), 93-101. (Read full article)
    19. Bejjani A, Burt L, Washington C, Terao M, Housri S, Housri N (2020). Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic. JCO Clin Cancer Inform, 4, 794-798. (Read full article)
    20. Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol, 148(3), 577-585. (Read full article)
    21. McComas KN, Torgeson AM, Ager BJ, Hellekson C, Burt LM, Maurer KA, Werner TL, Gaffney DK (2019). The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol, 156(1), 85-92. (Read full article)
    22. Ager BJ, Torgeson A, Francis SR, Burt LM, Gaffney DK, Cannon DM (2019). Impact of Brachytherapy Boost and Dose-escalated External Beam Radiotherapy in Margin Positive Cervical Cancer Treated With Chemotherapy and Radiation. Am J Clin Oncol, 43(1), 35-42. (Read full article)
    23. Ager BJ, Christensen MT, Burt LM, Poppe MM (2019). The value of high-dose radiotherapy in intracranial ependymoma. Pediatr Blood Cancer, 66(6), e27697. (Read full article)
    24. Park J, Blackburn BE, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Burt L, Werner T, Gaffney DK, Lopez AM, Mooney K, Hashibe M (2018). Rural-metropolitan disparities in ovarian cancer survival: a statewide population-based study. Ann Epidemiol, 28(6), 377-384. (Read full article)
    25. Burt LM, Shrieve DC, Tward JD (2018). Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Adv Radiat Oncol, 3(2), 170-180. (Read full article)
    26. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017). Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast, 35, 122-129. (Read full article)
    27. Bagshaw HP, Burt LM, Jensen RL, Suneja G, Palmer CA, Couldwell WT, Shrieve DC (2017). Adjuvant radiotherapy for atypical meningiomas. J Neurosurg, 126(6), 1822-1828. (Read full article)
    28. Burt LM, Trifiletti DM, Nabavizadeh N, Katz LM, Morris ZS, Royce TJ (2017). Supply and Demand for Radiation Oncology in the United States: A Resident Perspective. Int J Radiat Oncol Biol Phys, 97(2), 225-227. (Read full article)
    29. Gonzalez VJ, Hullett CR, Burt L, Rassiah-Szegedi P, Sarkar V, Tward JD, Hazard LJ, Huang YJ, Salter BJ, Gaffney DK (2017). Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy. Adv Radiat Oncol, 2(2), 235-243. (Read full article)
    30. Mattes MD, Patel KR, Burt LM, Hirsch AE (2016). A Nationwide Medical Student Assessment of Oncology Education. J Cancer Educ, 31(4), 679-686. (Read full article)
    31. Verma V, Burt L, Gimotty PA, Ojerholm E (2016). Contemporary Trends in Radiation Oncology Resident Research. Int J Radiat Oncol Biol Phys, 96(4), 915-918. (Read full article)
    32. Burt LM, Poppe MM, Kokeny KE, Gaffney DK, Shrieve DC, Tward JD (2016). Comparison of Treatments for Breast Cancer Arising after Radiation Treatment for Hodgkin’s Lymphoma. J Radiat Oncol, 6(1), 65-72.
    33. Burt LM, Orlandi RR, Hunt JP, Buchmann LO, Grossmann KF, Monroe MM, Shrieve DC, Hitchcock Y (2016). Function Preservation and Optimal Outcomes – Definitive Chemoradiotherapy with Multi-phase Treatment Planning for Locally Advanced Sinonasal Cancer. J Radiat Oncol, 5(1), 47-54.
    34. Nabavizadeh N, Burt LM, Mancini BR, Morris ZS, Walker AJ, Miller SM, Bhavsar S, Mohindra P, Kim MB, Kharofa J (2016). Results of the 2013-2015 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States. Int J Radiat Oncol Biol Phys, 94(2), 228-34. (Read full article)
    35. Karsy M, Hoang N, Barth T, Burt L, Dunson W, Gillespie DL, Jensen RL (2016). Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. World Neurosurg, 86, 210-9. (Read full article)
    36. Burt LM, Shrieve DC, Tward JD (2014). Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys, 88(1), 94-100. (Read full article)
    37. Bowen AR, Burt L, Boucher K, Tristani-Firouzi P, Florell SR (2012). Use of proliferation rate, p53 staining and perforating elastic fibers in distinguishing keratoacanthoma from hypertrophic lichen planus: a pilot study. J Cutan Pathol, 39(2), 243-50. (Read full article)
    38. Harris K, Vanderhooft L, Burt L, Vanderhooft S, Hull C (2012). Tanning business practices in Salt Lake County, Utah. J Am Acad Dermatol, 66(3), 513-514. (Read full article)

    Review

    1. Parsons MW, Huang YJ, Burt L, Suneja G, Gaffney D (2021). Vaginal cuff brachytherapy for endometrial cancer: a review of major clinical trials with a focus on fractionation. [Review]. Int J Gynecol Cancer, 32(3), 311-315. (Read full article)
    2. Tao R, Lloyd S, Burt L, Whisenant J, Garrido-Laguna I, Das P (2017). Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. [Review]. Curr Colorectal Cancer Rep, 13(2), 175-182. (Read full article)

    Book Chapter

    1. Burt LM, Suneja G, Shrieve DC (2018). Pituitary adenoma. In Burt LM|Suneja G|Shrieve DC (Ed.), Adult CNS Radiation Oncology: Principles and Practice (pp. 19-35). (Read full article)

    Letter

    1. Burt L, Gaffney D (2023). Take Your Best Shot Upfront! [Letter to the editor]. Int J Radiat Oncol Biol Phys, 118(2), 319-320. (Read full article)
    2. Harris K, Vanderhooft L, Burt L, Vanderhooft S, Hull C (2012). Tanning business practices in Salt Lake County, Utah. [Letter to the editor]. J Am Acad Dermatol, 66(3), 513-4. (Read full article)

    Other

    1. Gravbrot N, Weil CR, DeCesaris CM, Gaffney DK, Suneja G, Burt LM (2024). Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913. Eur J Cancer (202, p. 114017). England. (Read full article)
    2. Casper AC, Parsons MW, Chipman J, Burt LM Jr, Suneja G, Maurer KA, Gaffney DK (2021). Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol Oncol (162(2), pp. 454-460). United States. (Read full article)

  • News & Podcasts

    Huntsman Cancer Institute News

  • Clinical Trials